Liver transplantation and autoimmune liver diseases

Authors

  • Rodrigo Liberal,

    1. Institute of Liver Studies, King's College London School of Medicine at King's College Hospital, London, United Kingdom
    2. Faculty of Medicine, University of Porto, Porto, Portugal
    Search for more papers by this author
  • Yoh Zen,

    1. Institute of Liver Studies, King's College London School of Medicine at King's College Hospital, London, United Kingdom
    Search for more papers by this author
  • Giorgina Mieli-Vergani,

    1. Institute of Liver Studies, King's College London School of Medicine at King's College Hospital, London, United Kingdom
    Search for more papers by this author
  • Diego Vergani

    Corresponding author
    • Institute of Liver Studies, King's College London School of Medicine at King's College Hospital, London, United Kingdom
    Search for more papers by this author

Address reprint requests to Diego Vergani, M.D., Ph.D., F.R.C.P., Institute of Liver Studies, King's College London School of Medicine at King's College Hospital, Denmark Hill, London SE5 9RS, United Kingdom. Telephone: +44 203 2993357; FAX: +44 203 2994224; E-mail: diego.vergani@kcl.ac.uk

Abstract

Liver transplantation (LT) is an effective treatment for patients with end-stage autoimmune liver diseases such as primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis. Indications for LT for these diseases do not differ substantially from those used for other acute or chronic liver diseases. Despite the good outcomes reported, the recurrence of autoimmune liver disease is relatively common in the allograft. In addition, it has become apparent that autoimmunity and autoimmune liver disease can arise de novo after transplantation for nonautoimmune liver disorders. An awareness of the existence of recurrent autoimmune liver diseases and de novo autoimmune hepatitis after LT has important clinical implications because their management differs from the standard antirejection treatment and is similar to the management of classic autoimmune liver diseases in the native liver. Liver Transpl 19:1065-1077, 2013. © 2013 AASLD.

Ancillary